General
Preferred name
Plitidepsin
Synonyms
DEHYDRODIDEMNIN B ()
Aplidin ()
aplidin (plitidepsin) ()
Aplidine ()
PM90001 ()
P&D ID
PD016258
CAS
137219-37-5
Tags
available
natural product
drug
Drug indication
Multiple myeloma
Angioimmunoblastic T-cell Lymphoma
Drug Status
investigational
approved
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Plitidepsin was isolated from the sea squirt Aplidium albicans. It was found to have potent anti-tumour activity, that is mediated via modulation of human elongation factor 1-α (eEF1A) proteins and the translation process. Plitidepsin is also an immunomodulator and has antiviral properties.

SARS-CoV-2: The coronavirus exploits the eukaryotic (host) translation machinery to allow it to replicate. As a translation disruptor, plitidepsin has demonstrated in vivo anti-SARS-CoV-2 activity in mouse models of infection . Under in vitro experimental conditions plitidepsin inhibited SARS-CoV-2 replication more effectively than . (GtoPdb)
Compound Sets
7
Cayman Chemical Bioactives
34053
ChEMBL Drugs
CHEMBL451930
DrugBank
DB04977
DrugMAP
DMJ8AUE
Guide to Pharmacology
11396
MedChem Express Bioactive Compound Library
HY-16050
Natural product-based probes and drugs
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
1109.63
Hydrogen Bond Acceptors
15
Hydrogen Bond Donors
4
Rotatable Bonds
15
Ring Count
4
Aromatic Ring Count
1
cLogP
2.52
TPSA
284.74
Fraction CSP3
0.7
Chiral centers
12.0
Largest ring
23.0
QED
0.11
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biosynthetic Origin
Polyketide, Peptide (NRPS)
Therapeutic Indication
Anticancer
Pathway
Anti-infection
Cell Cycle/DNA Damage
Target
DNA/RNA Synthesis
SARS-CoV
Source data